MS is BIG dollar business! Biogen to pay $1.25 billion settlement in multiple sclerosis drug case.
Biogen to pay $1.25B settlement to Forward Pharma in Tecfidera patent case - Triangle Business Journal
The giant settlement and licensing agreement could help Cambridge biotech Biogen extend the life of its multiple sclerosis drug, Tecfidera, which accounts for around a third of its total revenue.
Add a comment...